BOEUF Stock Chart & Stats
$23.58
-$1.04(-4.34%)
At close: 4:00 PM EDT
$23.58
-$1.04(-4.34%)
Day’s Range― - ―
52-Week Range$17.66 - $34.14
Previous CloseN/A
Volume116.00
Average Volume (3M)82.00
Market Cap
$2.18B
Enterprise Value$14.61B
Total Cash (Recent Filing)$510.52M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)78.7
Beta0.48
Next Earnings
Feb 16, 2027EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.13
Shares Outstanding65,859,190
10 Day Avg. Volume128
30 Day Avg. Volume82
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market Cap6.71
Enterprise Value/Revenue10.43
Enterprise Value/Gross Profit11.36
Enterprise Value/Ebitda39.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)$153.36M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRapid sales growth across the core portfolio indicates expanding clinical adoption and commercial reach. Continued momentum in antibiotic-eluting CERAMENT, U.S. accounts, and international markets can strengthen operating leverage and support durable revenue compounding over the next several quarters.
Strong Profitability And Cash GenerationHigh operating margins combined with near-total cash conversion demonstrate that reported growth is translating into internally generated funds. This supports continued investment in commercial capabilities, clinical evidence, and product development without relying on additional capital.
Low Leverage And Reimbursement SupportA nearly debt-free balance sheet provides flexibility to fund expansion and absorb execution variability. Improved U.S. reimbursement and clearer coding should reduce administrative barriers over time, supporting hospital access and the commercial potential of infection-focused CERAMENT products.
Bears Say
Historical Cash-flow VolatilityAlthough current cash generation is strong, the recent inflection leaves less evidence across a full business cycle that conversion will remain consistent. Renewed volatility could constrain investment planning and make future profitability more dependent on sustained procedure growth.
Commercial Investment Pressures MarginsExpanding the U.S. and EUROW commercial organizations is supporting growth but is also increasing the cost base. If higher selling expenses and manufacturing costs persist faster than revenue gains, operating leverage and the durability of margin expansion could weaken.
Adoption And Regulatory Execution RiskHospital and surgeon adoption may remain uneven as customers evaluate outcomes, reimbursement, and administrative processes, slowing the conversion of interest into recurring use. CERAMENT V also depends on regulatory clearance, delaying a potentially important U.S. growth contribution.
BONESUPPORT HOLDING AB News
BOEUF FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was $17.66 and its highest was $34.14 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is $2.18B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Feb 16, 2027 which is in 107 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Oct 22, 2026. The company reported $0.141 earnings per share for the quarter, beating the consensus estimate of $0.134 by $0.007.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.15.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of $0.141 in its last earnings report, beating expectations of $0.134. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in BOEUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
BOEUF Company Deck
BOEUF Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, driven by 38% constant-currency sales growth, improved operating margins, strong cash generation, continued U.S. CERAMENT G adoption, favorable CMS reimbursement changes, and positive SOLARIO results. The company also reaffirmed full-year growth guidance and reported progress on CERAMENT V and its spine strategy. Offsetting factors included higher commercial costs, a decline in U.S. gross margin, flat CERAMENT BVF sales, continued go-stop-go adoption patterns, and pending regulatory and clinical milestones.View all BOEUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
8.46% Mutual Funds
― Other Institutional Investors
86.30% Public Companies and
Individual Investors